CSL Behring Seeks Proposals for the Third Annual Interlaken Leadership Awards
- Global Awards Program Funds Innovative Research in Neuroimmunology
KING OF PRUSSIA, Pennsylvania, Jan. 14, 2013 /PRNewswire/ -- Committed to improving the quality of life for people with rare and serious diseases, CSL Behring is calling for proposals for the 2013 Interlaken Leadership Awards. Established in 2010, this annual global awards program provides monetary grants and/or product supply to advance medical research and knowledge about the potential role of immunoglobulin (Ig) therapy in the treatment of neurological disorders.
"Performing daily activities can be extremely difficult for those living with a neurological disorder, and at times, the condition can even be debilitating," said Jeffrey Baggish, M.D., Director of Medical Affairs, Immunology & Pulmonary at CSL Behring. "We established the Interlaken Leadership Awards to fund innovative research that may improve the quality of life for those diagnosed with a neurological condition."
To date, the Interlaken Leadership Awards has provided $2 million in grants to research studying Ig therapy in areas such as neuromyelitis optica (NMO), Duchenne muscular dystrophy (DMD), complex regional pain syndrome (CRPS), acute ischemic stroke, paraneoplastic syndromes, and autoimmune peripheral neuropathies.
Proposal Submission Process and Eligibility
Any individual actively engaged in clinical or basic research of polyvalent immunoglobulins for neurological conditions is eligible for the Interlaken Leadership Awards.
For more information or to submit a proposal, please visit: www.InterlakenLeadershipAwards.com.
About the International Immunoglobulin Symposium in Interlaken
For more than three decades, CSL Behring has sponsored a high-level scientific symposium in Interlaken, Switzerland. First held in 1981, and most recently in 2009, the International Immunoglobulin Symposium focuses exclusively on scientific and clinical research in the field of polyvalent immunoglobulins.
Research presented at the Interlaken symposium is consistently at the forefront of immunoglobulin research. Since its inception, the International Immunoglobulin Symposium has won the respect and support of top international scientists and clinicians from many different fields of research. For more information, please visit: http://www.interlakenleadershipawards.com/symposium.aspx
About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn. For more information visit http://www.cslbehring.com/. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma.
Senior Manager, Public Relations & Communications
SOURCE CSL Behring
Skapa innehåll för din webbplats
Förbättra din webbplats eller blogg med PR Newswires skräddarsydda nyhetsflöden.
Kontakta PR Newswire
Skicka oss ett mail till email@example.com eller ring oss på +46 (0)739 44 89 87 eller +46 (0)739 44 36 18
Bli en PR Newswire kund
Begär mer information , se PR Newswire produkter & tjänster eller ring oss på +46 (0)739 44 89 87 eller +46 (0)739 44 36 18